Uniden­ti­fied wit­ness­es ac­cuse Bris­tol My­ers of scut­tling time­ly FDA move on liso-cel to avoid $6.4B pay­out

Back in June, dis­grun­tled Cel­gene share­hold­ers filed a law­suit against Bris­tol My­ers Squibb, ac­cus­ing the phar­ma gi­ant of pur­pose­ly slow-rolling Breyanzi’s ap­proval to avoid mak­ing a $6.4 bil­lion con­tin­gent val­ue rights (CVR) pay­out tied to its big Cel­gene ac­qui­si­tion.

Now, eight uniden­ti­fied wit­ness­es are com­ing forth to de­tail “a se­ries of de­lib­er­ate or reck­less acts” they say BMS took to slam the brakes on what they say could have been an oth­er­wise swift ap­proval for Breyanzi.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER